-
The Annals of Pharmacotherapy Jun 2004To report a case of generalized urticaria induced by montelukast treatment.
OBJECTIVE
To report a case of generalized urticaria induced by montelukast treatment.
CASE SUMMARY
A 28-year-old man with allergic rhinitis and moderate persistent asthma developed generalized urticaria 5 days after the initiation of montelukast and inhaled fluticasone. Symptoms disappeared within one day after suspension of both drugs. Two months later, after the resumption of montelukast and fluticasone, the patient developed generalized urticaria and eyelid angioedema, which were successfully treated with intravenous betamethasone, achieving complete remission within hours. After 2 days, the patient resumed inhaled fluticasone only and continued this therapy for several months without any adverse reaction.
DISCUSSION
We attributed the adverse reaction to montelukast because of the temporal relationship between use of montelukast and urticaria, the absence of other identified causative factors and other explanations for allergic reactions, and the positive dechallenge and rechallenge. The Naranjo probability scale showed a probable relationship between skin manifestations and montelukast treatment.
CONCLUSIONS
The use of antileukotrienes is increasing in asthma therapy. In cases of generalized urticaria in asthmatic patients undergoing montelukast therapy, physicians should be aware of a potential adverse reaction to this drug.
Topics: Acetates; Adult; Cyclopropanes; Humans; Leukotriene Antagonists; Male; Quinolines; Sulfides; Urticaria
PubMed: 15113985
DOI: 10.1345/aph.1D547 -
Minerva Medica Aug 2023
PubMed: 37534834
DOI: 10.23736/S0026-4806.23.08711-6 -
Thorax Mar 2001
Topics: Acetates; Adolescent; Adult; Asthma; Cyclopropanes; Cystic Fibrosis; Exercise Tolerance; Female; Humans; Leukotriene Antagonists; Male; Quinolines; Sulfides; Treatment Outcome
PubMed: 11245147
DOI: 10.1136/thorax.56.3.244a -
Annals of Neurology May 2023This study was undertaken to examine the association between montelukast use, β2-adrenoreceptor (β2AR) agonist use, and later Parkinson disease (PD).
OBJECTIVE
This study was undertaken to examine the association between montelukast use, β2-adrenoreceptor (β2AR) agonist use, and later Parkinson disease (PD).
METHODS
We ascertained use of β2AR agonists (430,885 individuals) and montelukast (23,315 individuals) from July 1, 2005 to June 30, 2007, and followed 5,186,886 PD-free individuals from July 1, 2007 to December 31, 2013 for incident PD diagnosis. We estimated hazard ratios and 95% confidence intervals using Cox regressions.
RESULTS
We observed 16,383 PD cases during on average 6.1 years of follow-up. Overall, use of β2AR agonists and montelukast were not related to PD incidence. A 38% lower PD incidence was noted among high-dose montelukast users when restricted to PD registered as the primary diagnosis.
INTERPRETATION
Overall, our data do not support inverse associations between β2AR agonists, montelukast, and PD. The prospect of lower PD incidence with high-dose montelukast exposure warrants further investigation, especially with adjustment for high-quality data on smoking. ANN NEUROL 2023;93:1023-1028.
Topics: Humans; Parkinson Disease; Acetates; Cyclopropanes; Quinolines
PubMed: 36897287
DOI: 10.1002/ana.26638 -
Medicine Dec 2021Cough variant asthma in children is a special type of asthma. Although there are many effective cases of combined acupuncture and western medicine in the clinical...
BACKGROUND
Cough variant asthma in children is a special type of asthma. Although there are many effective cases of combined acupuncture and western medicine in the clinical treatment of this kind of children, there is no standardized acupuncture combined with western medicine to evaluate the curative effect. Therefore, combined with existing reports, a systematic review and meta-analysis of acupuncture combined with montelukast sodium in the treatment of cough variant asthma in children were carried out to obtain conclusive results.
METHODS
The following electronic databases will be searched: PubMed, the Cochrane Library, Embase, Web of Science, Medline, CNKI, Chinese Biomedical Literature Database, VIP, and Wan Fang databases. We will consider articles published between database initiation and October 2021. We will use Review Manager 5.4, provided by the Cochrane Collaborative Network for statistical analysis. Clinical randomized controlled trials related to acupuncture combined with montelukast sodium on cough variant asthma in children were included in this study. Language is limited to both Chinese and English. Research selection, data extraction, and research quality assessments were independently completed by two researchers. We then assessed the quality and risk of the included studies and observed the outcome measures.
RESULTS
This study provides a high-quality synthesis to assess the effectiveness and safety of acupuncture combined with montelukast sodium on cough variant asthma in children.
CONCLUSION
This systematic review will provide evidence to determine whether acupuncture combined with montelukast sodium is an effective and safe intervention for patients with cough variant asthma in children.
INPLASY REGISTRATION NUMBER
INPLASY2021110006.
Topics: Acetates; Acupuncture Therapy; Anti-Asthmatic Agents; Asthma; Child; Combined Modality Therapy; Cough; Cyclopropanes; Humans; Meta-Analysis as Topic; Quinolines; Research Design; Sulfides; Systematic Reviews as Topic; Treatment Outcome
PubMed: 34941045
DOI: 10.1097/MD.0000000000028048 -
Korean Journal of Pediatrics Sep 2015The purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonarydysplasia (BPD).
PURPOSE
The purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonarydysplasia (BPD).
METHODS
The Interventional study was designed as a multicenter, prospective, and randomized trial, with open labeled and parallel-experimental groups, 66 infants were enrolled and allocated to either the case group (n=30) or the control group (n=36) based on gestational age (GA). Infants in the case group were given Montelukast sodium (Singulair) based on their body weight (BW). Zero week was defined as the start time of the study.
RESULTS
The incidence of moderate to severe BPD was not different between the groups (case group: 13 of 30 [43.3%] vs. control group: 19 of 36 [52.8%], P=0.912). Additionally, secondary outcomes such as ventilation index, mean airway pressure and resort to systemic steroids were not significantly different. There were no serious adverse drug reactions in either group, and furthermore the rate of occurrence of mild drug related-events were not significantly different (case group: 10 of 42 [23.8%] vs. control group: 6 of 48 (15.8%), P=0.414).
CONCLUSION
Montelukast was not effective in reducing moderate or severe BPD. There were no significant adverse drug events associated with Montelukast treatment.
PubMed: 26512261
DOI: 10.3345/kjp.2015.58.9.347 -
The Journal of Urology Oct 2015We assessed the nephroprotective effects of montelukast sodium and N-acetylcysteine on secondary renal damage due to unilateral ureteral obstruction in a rat model.
PURPOSE
We assessed the nephroprotective effects of montelukast sodium and N-acetylcysteine on secondary renal damage due to unilateral ureteral obstruction in a rat model.
MATERIALS AND METHODS
In this study 30 Wistar albino male rats were randomized into 3 groups, including placebo, N-acetylcysteine and montelukast sodium. Three rats served as the control group. The left ureter of the rats was sutured with 4-zero polyglactin sutures. Medications were given 3 days before obstruction and continued for 15 days. Dimercaptosuccinic acid renal scintigraphy was performed before obstruction and on day 15. Rats were sacrificed on day 15 and histopathological examinations were done. We biochemically assessed oxidative stress markers (myeloperoxidase and malondialdehyde), sulfhydryl and total nitrite for lipid peroxidation, oxidative protein damage and antioxidant levels, respectively.
RESULTS
On pathological examination inflammation and tubular epithelial damage in the N-acetylcysteine and montelukast sodium groups were less than in the placebo group (p <0.05). No difference was seen in normal kidneys. Myeloperoxidase, malondialdehyde and total nitrite levels in the N-acetylcysteine group, and myeloperoxidase and malondialdehyde levels in the montelukast sodium group were lower than in the placebo group (p <0.05). No statistical difference was seen in sulfhydryl levels (p >0.05) or among the N-acetylcysteine, montelukast sodium and placebo groups on scintigraphy (p >0.05). No pathological, chemical and scintigraphic differences were seen among the N-acetylcysteine, montelukast sodium and sham treated groups (p >0.05).
CONCLUSIONS
N-acetylcysteine and montelukast sodium have a protective effect against obstructive damage of the kidney. However, further investigations are needed.
Topics: Acetates; Acetylcysteine; Animals; Cyclopropanes; Disease Models, Animal; Kidney Diseases; Male; Placebos; Quinolines; Randomized Controlled Trials as Topic; Rats; Rats, Wistar; Sulfides; Ureteral Obstruction
PubMed: 25776910
DOI: 10.1016/j.juro.2015.03.003 -
Indian Journal of Pediatrics Apr 2006Leukotriene modifiers (receptor antagonist and biosynthesis inhibitor) represent the first mediator specific therapeutic option for asthma. Montelukast, a leukotriene... (Review)
Review
UNLABELLED
Leukotriene modifiers (receptor antagonist and biosynthesis inhibitor) represent the first mediator specific therapeutic option for asthma. Montelukast, a leukotriene receptor antagonist is the only such agent approved for use in pediatric patients. Montelukast modifies action of leukotrienes, which are the most potent bronchoconstrictors, by blocking Cysteinyl leukotriene receptors. Systemic drug like mountelukast can reach lower airways and improves the peripheral functions which play a crucial role in the evolution of asthma. Review of existing literature showed that montelukast compared to placebo has proven clinical efficacy in better control of day time asthma symptoms, percentage of symptom free days, need for rescue drugs and improvement in FEV 1. Studies also demonstrated improvement in airway inflammation as indicated by reduction in fractional exhaled nitric oxide, a marker of inflammation. Studies comparing low dose inhaled corticosteroids (ICS) with montelukast are limited in children and conclude that it is not superior to ICS. For moderate to severe persistent asthma, montelukast has been compared with long acting beta agonists (LABA) as an add-on therapy to ICS, montelukast was less efficacious and less cost-effective. It has beneficial effects in exercise induced asthma and aspirin-sensitive asthma. Montelukast has onset of action within one hour. Patient satisfaction and compliance was better with montelukast than inhaled anti-inflammatory agents due to oral, once a day administration. The recommended doses of montelukast in asthma are- children 1-5 years: 4 mg chewable tablet, children 6-14 years: 5mg chewable tablet,
ADULTS
10mg tablet; administered once daily. The drug is well tolerated. Based on the presently available data montelukast may be an alternative treatment for mild persistent asthma as monotherapy where ICS cannot be administered. It is also an alternative to LABA as an add-on therapy to ICS for moderate to severe persistent asthma. The other indications for use of montelukast include: allergic rhinitis, exercise induced bronchoconstriction and aspirin-induced asthma.
Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Asthma; Bronchial Diseases; Child; Constriction, Pathologic; Cyclopropanes; Humans; Infant; Leukotriene Antagonists; Practice Guidelines as Topic; Quinolines; Randomized Controlled Trials as Topic; Rhinitis, Allergic, Seasonal; Sulfides
PubMed: 16816486
DOI: 10.1007/BF02825818 -
Paediatric Respiratory Reviews Mar 2015Leukotriene receptor antagonists were introduced as an entirely new concept in asthma therapy, which indeed they are. However, although an intellectually new concept,... (Review)
Review
Leukotriene receptor antagonists were introduced as an entirely new concept in asthma therapy, which indeed they are. However, although an intellectually new concept, they have largely disappointed in clinical practice. A small minority of school age asthmatics may respond better to these medications as against inhaled corticosteroids as prophylactic therapy. In children not responding to low dose inhaled corticosteroids, the best add-on therapy is salmeterol, but a small number respond better to Montelukast. In pre-school wheeze, intermittent Montelukast may be an effective strategy in some children who wheeze just with viral colds, but the clinical trial data are controversial. Pre-schoolers with multiple trigger wheeze are probably best treated with inhaled corticosteroids. What is clear is that clinically, a higher proportion of children are prescribed Montelukast than would be predicted from the lterature to respond to the medication. No biomarker to predict response to Montelukast has reached clinical practice, so N of 1 clinical trials should be performed. It is important not to leave children on Montelukast if there is no convincing response to this treatment.
Topics: Acetates; Administration, Inhalation; Anti-Asthmatic Agents; Asthma; Child; Child, Preschool; Cyclopropanes; Glucocorticoids; Humans; Leukotriene Antagonists; Quinolines; Sulfides
PubMed: 25499571
DOI: 10.1016/j.prrv.2014.10.007 -
International Journal of Pharmaceutics Sep 2020The main objectives of this work were to develop and characterize new 3D printing filaments and print them directly onto a packaging material. Different blends of...
The main objectives of this work were to develop and characterize new 3D printing filaments and print them directly onto a packaging material. Different blends of polymers were tested to achieve low-temperature printing filaments, which are flexible and durable to be wound onto spools. The mechanical properties of filaments were compared with commercial filaments and evaluated by bending tests. Kollidon 12PF, PEG 4000, and PEO 900k blends resulted in promising filaments that could be extruded at 70 °C and had flexibility similar to commercial PLA filaments. Montelukast sodium (MS), which undergoes hepatic first-pass metabolism, was compounded into polymer blends, and drug-loaded filaments were extruded. All filaments were tested with a 3D printing pen prior to using with the 3D printer for transdermal patches. MS loaded filaments and patches showed similar flexibility with placebo. In vitro drug release studies showed 52% of MS was released in 24 h. Printing on disposable packaging material is presented for the first time with this study. Build plate adhesion and cohesion of 3D printed layers were successfully achieved. This new technique could prevent cross-contamination, save time, and provide ease of use, which can take us one step closer to the production of personalized drugs in pharmacies.
Topics: Acetates; Cyclopropanes; Drug Liberation; Printing, Three-Dimensional; Quinolines; Sulfides
PubMed: 32663585
DOI: 10.1016/j.ijpharm.2020.119588